IKT — Inhibikase Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1750149 ·
Last close
$2.06
Market Cap
$287.44M
52W High
$2.61
52W Low
$1.33
ADV30
500,783
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -21,050,995 | -19,591,231 | 163,588,612 | 31,206,707 | 10,260,026 |
| Mar 2026 | 0 | — | -18,215,273 | -16,380,840 | 173,332,227 | 49,573,510 | 5,711,959 |
| Dec 2025 | 0 | — | -13,133,457 | -12,734,651 | 181,204,516 | 139,220,208 | 8,300,837 |
| Sep 2025 | 0 | — | -13,261,200 | -11,930,280 | 79,594,541 | 38,269,706 | 6,696,243 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-35,742,656
Investing CF
$-99,485,799
Financing CF
$111,360,574
CapEx
$-452,023
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.49
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-159,060,640
Inventory
—
Receivables
—
ST Investments
$120,795,235
EBIT TTM
$-55,800,628
Pretax Income TTM
$-50,961,294
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -53,348,225 | -48,259,189 | 181,204,516 | 8,300,837 | 172,903,679 | -27,786,464 |
| Dec 2024 | 0 | -28,589,068 | -27,519,886 | 98,599,846 | 3,733,566 | 94,866,280 | -19,148,067 |
| Dec 2023 | 0 | -20,089,792 | -19,028,883 | 14,506,647 | 3,528,725 | 10,977,922 | -18,085,043 |
| Dec 2022 | 0 | -18,128,608 | -18,054,155 | 24,936,297 | 3,900,896 | 21,035,401 | -17,351,103 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.43
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FATE | FATE THERAPEUTICS INC | $281.58M | $2.35 | — |
| XFOR | X4 Pharmaceuticals, Inc | $298.43M | $3.01 | — |
| SABS | SAB Biotherapeutics, Inc. | $299.35M | $3.29 | — |
| IVVD | Invivyd, Inc. | $275.30M | $0.93 | — |
| IPSC | Century Therapeutics, Inc. | $302.40M | $1.67 | — |
News headlines (Yahoo Finance, 1h cache)
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
2026-08-11 20:01 · Yahoo
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
2026-07-23 12:00 · Yahoo
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
2026-07-14 12:00 · Yahoo
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 20:01 · Yahoo
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
2026-04-07 12:00 · Yahoo
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
2026-05-12 20:01 · Yahoo
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
2026-02-22 11:15 · Yahoo
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
2025-11-21 02:54 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.